1,3-bis(4-methoxyphenyl)-2-propanamine | 1017130-67-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: 1,3-bis(4-methoxyphenyl)-2-propanamine
• 英文别名: di-p-anisylmethylamine；dianisylmethylamine；DAM-NH2；1,3-Bis(4-methoxyphenyl)propan-2-amine
• CAS: 1017130-67-4
• 化学式: C₁₇H₂₁NO₂
• 分子量: 271.359
• InChiKey: YFLVXCSDWUZHCZ-UHFFFAOYSA-N

物化性质

• 沸点：
  408.8±35.0 °C(Predicted)
• 密度：
  1.078±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,3-bis(4-methoxyphenyl)-2-propanamine 在 palladium diacetate 、 copper(II) acetate monohydrate 、 caesium carbonate 、 三乙胺 、 (R)-(+)-N-(2'-hydroxy-[1,1']binaphthalenyl-2-yl)acetamide 作用下， 以 二氯甲烷 、 二甲基亚砜 、 甲苯 为溶剂， 反应 18.5h， 生成 (R)-1-cyclohexylidene-8-methoxy-4-(4-methoxybenzyl)-3-((trifluoromethyl)sulfonyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine
  参考文献：
  名称：

  基于联萘支架的手性配体用于 Pd 催化的对映选择性 C-H 活化/环加成反应

  摘要：

  我们报告了使用一类新型配体 (NOBINAc) 使用钯催化剂进行不对称 C-H 活化的第一个例子。这些配体将联萘支架的轴向手性与单 N 保护氨基酸 (MPAA) 的双功能和双齿配位特性相结合，众所周知，MPAA 通过协调的金属化-去质子化机制有利于 Pd 促进的 C-H 活化。我们证明，我们的新配体通过高苄基三氟酰胺或邻甲基苄基三氟酰胺和丙二烯之间的正式 (5 + 2) 环加成反应，在组装 2-苯并氮杂卓时，能够实现比 MPAA 更高的对映选择性。

  DOI：

  10.1021/jacs.2c09479
• 作为产物：
  描述：

  1-甲氧基-4-(2-硝基乙基)苯 在 potassium fluoride 、 lithium aluminium tetrahydride 、 盐酸二甲胺 作用下， 以 四氢呋喃 、 甲苯 、 苯 为溶剂， 反应 27.0h， 生成 1,3-bis(4-methoxyphenyl)-2-propanamine
  参考文献：
  名称：

  Synthesis and serotonin transporter activity of 1,3-bis(aryl)-2-nitro-1-propenes as a new class of anticancer agents

  摘要：

  Structural derivatives of 4-MTA, an illegal amphetamine analogue have been previously shown to have anticancer effects in vitro. In this study we report the synthesis of a series of novel 1,3-bis(aryl)-2-nitro-1-propene derivatives related in structure to 4-MTA. A number of these compounds containing a classic nitrostyrene structure are shown to have antiproliferative activities in vitro in a range of malignant cell lines, particularly against Burkitt's lymphoma derived cell lines, whilst having no effect on 'normal' peripheral blood mononuclear cells. Such effects appear to be independent of the serotonin transporter, a high affinity target for amphetamines and independent of protein tyrosine phosphatases and tubulin dynamics both of which have been previously associated with nitrostyrene-induced cell death. We demonstrate that a number of these compounds induce caspase activation, PARP cleavage, chromatin condensation and membrane blebbing in a Burkitt's lymphoma derived cell line, consistent with these compounds inducing apoptosis in vitro. Although no specific target has yet been identified for the action of these compounds, the cell death elicited is potent, selective and worthy of further investigation. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.11.054

文献信息

• 2,4-Pyrimidinediamine Compounds and Their Uses
  申请人：Singh Rajinder

  公开号：US20150266828A1

  公开（公告）日：2015-09-24

  The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

  本发明提供了抑制IgE和/或IgG受体信号级联反应的2,4-嘧啶二胺化合物，该级联反应导致化学介质的释放，以及合成这些化合物的中介体和方法，以及在多种情况下使用这些化合物的方法，包括在治疗和预防由脱粒和其他由IgE和/或IgG受体信号级联反应激活引起的化学介质释放所表征、引起或相关的疾病。
• Novel substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators
  申请人：——

  公开号：US20030073842A1

  公开（公告）日：2003-04-17

  The invention is directed to substituted benzimidazol-2-ones of Formula I, 1 wherein A, X, Y, m, n, R 1 , R 2 , R 3 , R 4 , and R 5 are as described in the specification, which are useful as vasopressin receptor antagonists or Neuropeptide Y Modulators for treating conditions such as aggression, obsessive-compulsive disorders, hypertension, dysmenorrhea, congestive heart failure/cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, renal vasospasm, renal failure, edema, ischemia, stroke, thrombosis, water retention, nephrotic syndrome, central nervous injuries, obesity, anorexia, hyperglycemia, diabetes, anxiety, depression, asthma, memory loss, sexual dysfunction, disorders of sleep and other circadian rhythms, and Cushing's disease.

  该发明涉及Formula I的取代苯并咪唑酮，其中A、X、Y、m、n、R1、R2、R3、R4和R5如说明书中所述，其可用作抗利尿素受体拮抗剂或神经肽Y调节剂，用于治疗侵略性、强迫症障碍、高血压、痛经、充血性心力衰竭/心脏不全、冠状动脉痉挛、心肌缺血、肝硬化、肾血管痉挛、肾功能衰竭、水肿、缺血、中风、血栓形成、水潴留、肾症候群、中枢神经损伤、肥胖、厌食、高血糖、糖尿病、焦虑、抑郁、哮喘、记忆丧失、性功能障碍、睡眠障碍和其他生物钟紊乱症状，以及库欣综合征。
• Ammonia synthons for the multicomponent assembly of complex γ-lactams
  作者：Darlene Q. Tan、Kevin S. Martin、James C. Fettinger、Jared T. Shaw

  DOI：10.1073/pnas.1015261108

  日期：2011.4.26

  The synthesis of gamma-lactams that are unsubstituted at the 1-position (nitrogen) as well as their subsequent N-functionalization is reported. A recently discovered four-component reaction (4CR) is employed with either an ammonia precursor or a protected form of ammonia that can be deprotected in a subsequent synthetic step. These methods represent the first multicomponent assembly of complex lactam

  报道了在 1-位（氮）处未取代的 γ-内酰胺的合成以及它们随后的 N-功能化。最近发现的四组分反应 (4CR) 与氨前体或受保护形式的氨一起使用，可在随后的合成步骤中脱保护。这些方法代表了第一个未取代氮的复杂内酰胺结构的多组分组装。此外，还报道了两种通过原始 4CR 不可能引入的氮取代基的方法。
• Homologation of α-aryl amino acids through quinone-catalyzed decarboxylation/Mukaiyama–Mannich addition
  作者：Benjamin J. Haugeberg、Johnny H. Phan、Xinyun Liu、Thomas J. O'Connor、Michael D. Clift

  DOI：10.1039/c7cc00485k

  日期：——

  A new method for amino acid homologation by way of formal C-C bond functionalization is reported.

  报道了通过正式CC键功能化进行氨基酸同源化的新方法。
• HIV integrase inhibitors
  申请人：——

  公开号：US20030181490A1

  公开（公告）日：2003-09-25

  The present invention relates to the inhibition of HIV integrase, and to the treatment of AIDS or ARC by administering compounds of the formula 1 wherein R 1 is C 1 -C 4 alkyl, carbocyclic radical, heterocyclic radical, aryl-C 1 -C 2 alkylene, aryloxy-C 1 -C 2 alkylene, alkoxy-CC(O)—, wherein R 1 is optionally substituted from 1-3 times with halo, C 1 -C 2 alkyl or C 1 -C 2 alkoxy, or R 1 is H; R 2 is H or C 1 -C 4 alkyl; R 3 is H, C 1 -C 4 alkyl or phenyl-C 0 -C 2 alkylene which is optionally substituted with 1-3 R 5 ; R 4a is carbocylic radical, heterocyclic radical, aryloxy, aryl-C 1 -C 4 alkylene, aryl-cyclopropylene, aryl-NHC(O)—, wherein R 4a is optionally substituted with 1-3 R 5 ; and wherein each R 5 is independently selected from H, halo, C 1 -C 4 alkyl, C 1 -C 4 alkenyl, C 1 -C 4 haloalkyl, C 1 -C 4 alkoxy, R 6 -phenyl, R 6 -phenoxy, R 6 -benzyl, R 6 -benzyloxy, NH 2 C (O)—, alkyl-NHC(O)—, wherein R 6 is H, halo; Z is a bond or a substituted or unsubstituted C 1 -C 4 alkylene group; and B 2 is 2

  本发明涉及抑制HIV整合酶的化合物，并通过给予式1中的化合物治疗艾滋病或ARC，其中R1为C1-C4烷基，碳环基，杂环基，芳基-C1-C2烷基，芳氧基-C1-C2烷基，烷氧基-CC（O）-，其中R1可以用卤素，C1-C2烷基或C1-C2烷氧基从1-3次取代，或R1为H；R2为H或C1-C4烷基；R3为H，C1-C4烷基或苯基-C0-C2烷基，该苯基-C0-C2烷基可以选择性地用1-3个R5取代；R4a为碳环基，杂环基，芳氧基，芳基-C1-C4烷基，芳基环丙基，芳基-NHC（O）-，其中R4a可以选择性地用1-3个R5取代；每个R5都是独立选择的H，卤素，C1-C4烷基，C1-C4烯基，C1-C4卤代烷基，C1-C4烷氧基，R6-苯基，R6-苯氧基，R6-苄基，R6-苄氧基，NH2C（O）-，烷基-NHC（O）-，其中R6为H，卤素；Z为键或取代或未取代的C1-C4烷基；B2为2。